Isracann Bioscience Inc. (ISCNF)

[goupupup]

It is well known that demand for cannabis in Israel exceeds supply as they are currently importing cannabis into the country, ISCNF announced that they will be importing cannabis from Canada for sale into the Israeli and European markets. This should jump start medical cannabis revenue by mid 2021. ISCNF also announced they will be ready to plant in March 2021 and with their processing facility complete, they could be market ready for sale of their home grown cannabis by late 2021. Therefore, it is reasonable to expect they could ramp revenue to $1 million a month in 2022 and the business model is very similar to IM Cannabis (CSE:IMCC, OTC:IMCNF) which is also an Israeli cannabis company. They are doing about a $1 million a month in revenue with 165 million shares outstanding. Their shares currently trade for about CDN $2.50 (USD $2.00) a share, so as a comparable, one might conclude this Co. could trade at CDN $2.50 (US $2.00) when they reach the $1 million a month milestone in 2022. As an added kicker Israel is set to legislate the approval of adult-use cannabis by the end of 2021, so this could turbo-charge revenue to drive their share price to $3 to $4 in 2022. This is a double sometime this year .. GOOD LUCK LONGS